UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $325,000 Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 7,647 shares of the company’s stock, valued at approximately $325,000.

Other institutional investors have also made changes to their positions in the company. Calamos Advisors LLC acquired a new stake in shares of GeneDx in the second quarter worth $1,137,000. Bank of New York Mellon Corp bought a new stake in GeneDx in the 2nd quarter valued at $991,000. nVerses Capital LLC acquired a new stake in GeneDx in the 2nd quarter worth $50,000. Rhumbline Advisers increased its holdings in shares of GeneDx by 8,096.4% during the 2nd quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock worth $480,000 after purchasing an additional 18,136 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of GeneDx during the 2nd quarter worth about $34,000. 61.72% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 2,154 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40. Following the sale, the chief executive officer now owns 105,426 shares in the company, valued at approximately $7,021,371.60. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder School Of Medicine At Mo Icahn sold 20,359 shares of GeneDx stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $69.78, for a total value of $1,420,651.02. Following the completion of the transaction, the insider now directly owns 2,846,474 shares of the company’s stock, valued at $198,626,955.72. This represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,123,603 shares of company stock worth $83,300,382 in the last quarter. 27.30% of the stock is owned by corporate insiders.

GeneDx Stock Up 2.8 %

NASDAQ WGS opened at $77.40 on Friday. GeneDx Holdings Corp. has a 1-year low of $2.47 and a 1-year high of $89.11. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -24.89 and a beta of 2.03. The stock’s 50 day moving average is $72.46 and its two-hundred day moving average is $47.35. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.82) EPS. Equities analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on WGS. Craig Hallum lifted their target price on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company raised their price objective on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.